Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Seung Up Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Results: Of the total study population, 146 (43.7%) patients had HS (CAP >238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA <12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P =0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P =0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P =0.022). Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.

Original languageEnglish
Pages (from-to)283-293
Number of pages11
JournalClinical and Molecular Hepatology
Volume25
Issue number3
DOIs
Publication statusPublished - 2019 Sep

Fingerprint

Tenofovir
Chronic Hepatitis B
Hepatitis B e Antigens
Liver
Elasticity Imaging Techniques
Hepatocellular Carcinoma
entecavir

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Molecular Biology

Cite this

@article{fc9cb403708d41d4a5773a0c83c041a2,
title = "Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir",
abstract = "Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Results: Of the total study population, 146 (43.7{\%}) patients had HS (CAP >238 dB/m). Three-hundred-three patients (90.7{\%}) achieved complete virological response (CVR) (hepatitis B virus DNA <12 IU/L), and 25 patients (7.5{\%}) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5{\%}), 37 (21.5{\%}) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P =0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P =0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P =0.022). Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.",
author = "Kim, {David Sooik} and Jeon, {Mi Young} and Lee, {Hye Won} and Kim, {Beom Kyung} and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Han, {Kwang Hyub} and Kim, {Seung Up}",
year = "2019",
month = "9",
doi = "10.3350/cmh.2018.0054",
language = "English",
volume = "25",
pages = "283--293",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "3",

}

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. / Kim, David Sooik; Jeon, Mi Young; Lee, Hye Won; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang Hyub; Kim, Seung Up.

In: Clinical and Molecular Hepatology, Vol. 25, No. 3, 09.2019, p. 283-293.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

AU - Kim, David Sooik

AU - Jeon, Mi Young

AU - Lee, Hye Won

AU - Kim, Beom Kyung

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

AU - Kim, Seung Up

PY - 2019/9

Y1 - 2019/9

N2 - Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Results: Of the total study population, 146 (43.7%) patients had HS (CAP >238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA <12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P =0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P =0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P =0.022). Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.

AB - Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Results: Of the total study population, 146 (43.7%) patients had HS (CAP >238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA <12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P =0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P =0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P =0.022). Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.

UR - http://www.scopus.com/inward/record.url?scp=85073463846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073463846&partnerID=8YFLogxK

U2 - 10.3350/cmh.2018.0054

DO - 10.3350/cmh.2018.0054

M3 - Article

C2 - 30419649

AN - SCOPUS:85073463846

VL - 25

SP - 283

EP - 293

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 3

ER -